Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
S&P 500   3,973.01 (+0.23%)
DOW   33,912.37 (+0.19%)
QQQ   282.07 (-0.23%)
AAPL   143.38 (-0.58%)
MSFT   240.66 (-0.45%)
META   109.54 (+0.70%)
GOOGL   95.11 (-0.98%)
AMZN   93.08 (-0.93%)
TSLA   183.41 (+0.27%)
NVDA   157.93 (-0.21%)
NIO   10.78 (+6.52%)
BABA   79.90 (+5.30%)
AMD   73.76 (+0.78%)
T   18.86 (+0.21%)
MU   56.08 (+0.59%)
CGC   3.43 (+0.88%)
F   13.78 (+0.36%)
GE   85.46 (-0.01%)
DIS   95.59 (-0.10%)
AMC   7.31 (-0.27%)
PYPL   80.03 (+0.13%)
PFE   49.54 (-0.06%)
NFLX   279.72 (-0.52%)
NASDAQ:CLBS

Caladrius Biosciences - CLBS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.43
$8.38
52-Week Range
N/A
Volume
466,373 shs
Average Volume
522,308 shs
Market Capitalization
$26.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.00
CLBS stock logo

About Caladrius Biosciences (NASDAQ:CLBS) Stock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLBS Stock News Headlines

CLBS Caladrius Biosciences, Inc.
See More Headlines

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLBS Company Calendar

Last Earnings
11/04/2021
Today
11/29/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLBS
Employees
27
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$90.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$90.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.54 per share

Miscellaneous

Free Float
59,250,000
Market Cap
$26.05 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 65)
    B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director
    Comp: $957.69k
  • Dr. Kristen K. Buck M.D. (Age 48)
    Exec. VP of R&D and Chief Medical Officer
    Comp: $825k
  • Mr. James Nisco
    VP of Fin. & Treasury
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    VP of Investor Relations & Corp. Communications
  • Eric Powers
    Director of Communications and Marketing
  • Ms. Gail Holler (Age 63)
    VP of HR
  • Dr. Ian Zhang Ph.D. (Age 57)
    MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
  • Dr. William K. Sietsema Ph.D. (Age 66)
    VP of Global Regulatory Affairs













CLBS Stock - Frequently Asked Questions

Should I buy or sell Caladrius Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLBS shares.
View CLBS analyst ratings
or view top-rated stocks.

What is Caladrius Biosciences' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month price targets for Caladrius Biosciences' stock. Their CLBS share price forecasts range from $90.00 to $90.00. On average, they predict the company's share price to reach $90.00 in the next twelve months.
View analysts price targets for CLBS
or view top-rated stocks among Wall Street analysts.

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) EPS for the quarter, topping analysts' consensus estimates of ($1.95) by $0.15. During the same quarter in the previous year, the business posted ($4.35) earnings per share.

When did Caladrius Biosciences' stock split?

Shares of Caladrius Biosciences reverse split on the morning of Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend.

What other stocks do shareholders of Caladrius Biosciences own?
What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

Who are Caladrius Biosciences' major shareholders?

Caladrius Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%). Insiders that own company stock include Michael H Davidson and Steven S Myers.
View institutional ownership trends
.

How much money does Caladrius Biosciences make?

Caladrius Biosciences (NASDAQ:CLBS) has a market capitalization of $0.00. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The official website for the company is www.caladrius.com. The biotechnology company can be reached via phone at (908) 842-0100, via email at jmenditto@caladrius.com, or via fax at 646-514-7787.

This page (NASDAQ:CLBS) was last updated on 11/29/2022 by MarketBeat.com Staff